Home World News FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer World News FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer By Ogkologos - June 27, 2025 555 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ARANOTE study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Can Artificial Intelligence Help See Cancer in New, and Better, Ways? March 22, 2022 Second-line Sintilimab Improves Survival Over Docetaxel in Squamous Non-Small Cell Lung... December 11, 2020 Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian... April 21, 2026 Similar Efficacy Between Subcutaneous and Intravenous Pembrolizumab Given with Chemotherapy for... April 14, 2025 Load more HOT NEWS FDA Approves Abatacept for Prophylaxis of Acute Graft Versus Host Disease Workout Wednesdays – Chest Exercises Part 1 Genetic Testing for Bladder Cancer: What People With Cancer and Their... ESMO Asia Congress 2024, Singapore, 6-8 December
